The global specimen validity testing market size is expected to reach USD 2.10 Billion by 2028 at a CAGR of 6.6%, according to the latest report by Reports and Data. Rapidly rising incidence of drug abuse, increasing number of drug screening labs across the globe, and growing demand for presumptive tests are key factors expected to drive market revenue growth over the forecast period. Presence of stringent regulations that mandate drug screening tests and increasing adoption of drug screening at workplace are also expected to contribute to market growth going ahead. Rising use of illicit drugs and growing diversion of prescription drugs is also expected to drive market growth going ahead.

Specimen Validity Testing (SVT) is performed on urine specimen to detect adulteration, substitution, or dilution. Specimen validation testing plays a crucial role in the healthcare sector as it allows clinicians to assess patient’s behavior, medicine adherence, and honesty in communication. Clinicians generally order SVT to make informed therapeutic decisions about medical conditions of their patients, which also includes therapeutic overuse and illicit drug abuse. Specimen validity testing enables clinicians and toxicologists ensure the integrity of the test through accurate measurements of creatinine, pH, and specific gravity. This has boosted its adoption in law enforcement agencies and in criminal justice and this is expected to drive market growth going ahead.

Access Free sample PDF Copy of the Report @ https://www.reportsanddata.com/sample-enquiry-form/4098

Rapid adoption of urine drug testing at workplace has contributed significantly to revenue growth of the global specimen validity testing market. Specimen validity testing and urine drug screening are crucial tools that allow employers enhance workplace safety and this is expected further fuel market growth going ahead. Growing awareness regarding drug screening tests and increasing efforts by governments to encourage specimen validity testing and drug screening and research programs are also expected to drive revenue growth of the market over the forecast period. However, availability of alternative drug screening tests is expected to restrain market growth to a certain extent over the forecast period.

Some Key Highlights From the Report:

• Reagents, calibrators, and controls segment is expected to account for largest revenue share among the products segment. Growth can be attributed to increasing demand and repeated purchase of reagents due to rising number of specimens being tested in drug screening laboratories.
• Laboratory testing segment is expected to register robust revenue CAGR over the forecast period owing to increasing drug testing in established healthcare facilities, rising cases of drug abuse, and implementation of standardized specimen validity testing protocols in laboratories.
• Workplace segment is expected to register significant revenue growth over the forecast period owing to rising incidence of drug abuse at workplaces and increasing number of offices and organizations mandating workplace drug screening.
• North America is expected to account for largest revenue share between 2021 and 2028, attributable to growing use of illicit drugs, increasing incidence of prescription diversion, and presence of stringent laws mandating drug screening in countries in the region.
• Key companies in the market include Thermo Fisher Scientific, Inc., Sciteck, American Bio Medica Corporation, Alere, Express Diagnostics, Premier Biotech, LabCorp., Quest Diagnostics, Alere Toxicology, ACM Global Laboratories, Clinical Reference Laboratory (CRL), SureHire, and CannAmm.

Request for Custom Research @ https://www.reportsanddata.com/request-customization-form/4098

For the purpose of this report, Reports and Data has segmented the global specimen validity testing market based on product & services, type, end-use, and region:  

Product & Services Outlook (Revenue, USD Billion; 2018-2028)

• Products
  • Reagents, Calibrators, & Controls
  • Assay Kits
  • Disposable
• Services

Type Outlook (Revenue, USD Billion; 2018-2028)

• Laboratory Testing
• Rapid/POC Testing

End-use Outlook (Revenue, USD Billion; 2018-2028)

• Workplaces
• Drug Screening Laboratories
• Law Enforcement Agencies
• Pain Management Centres
• Drug Rehabilitation Centres
• Others

Get Attractive Discount @ https://www.reportsanddata.com/discount-enquiry-form/4098

Regional Outlook (Revenue, USD Billion; 2018-2028)

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • U.K.
  • Italy
  • France
  • BENELUX
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of APAC
• Latin America
  • Brazil
  • Rest of LATAM
• Middle East & Africa
  • Saudi Arabia
  • U.A.E.
  • South Africa
  • Rest of MEA

Buy now your Exclusive copy of Report @ https://www.reportsanddata.com/checkout-form/4098

Explore Reports and Data's Prime Analysis of the global Healthcare & Pharmaceutical Industry:

Predictive Genetic Testing & Consumer/Wellness Genomics Market Size, Share & Analysis, By Type (On-Premise, Cloud Based), By Application (Predictive Genetic Testing & Consumer Genomics, Wellness Genomics), By Setting Type (Clinic, Direct To Consumer, Hospital), And By Region Forecast To 2028

Ovarian Cancer Diagnostics Market Size, Share & Analysis, By Cancer Type (Epithelial Tumour, Germ Cell Tumour, Stromal Cell Tumour, Others), by Diagnosis Type (Biopsy, Blood Test, Imaging And Others), By End-Use (Hospital Laboratories, Cancer Diagnostic Centres, Research Institutes, Others), And By Region, Global Forecast To 2028

About Reports and Data

Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help client’s make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Power and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise.

Contact Us:

John W

Head of Business Development

Reports and Data | Web: www.reportsanddata.com

Direct Line: +1-212-710-1370

E-mail: sales@reportsanddata.com